{
    "clinical_study": {
        "@rank": "139676", 
        "arm_group": [
            {
                "arm_group_label": "1a USDD", 
                "arm_group_type": "Active Comparator", 
                "description": "Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months"
            }, 
            {
                "arm_group_label": "1b USDD", 
                "arm_group_type": "No Intervention", 
                "description": "Patients control, no drug"
            }, 
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "No Intervention", 
                "description": "Control Group, no disease, no drug"
            }
        ], 
        "brief_summary": {
            "textblock": "Diverticulosis of the colon is a frequent condition in adults in western countries and a\n      significant number of patients experience clinical symptoms even when the diverticulosis is\n      not complicated by diverticulitis.\n\n      Both central and mucosal immunity are altered in Uncomplicated Symptomatic  Diverticular\n      Disease (USDD) and Rifaximin ameliorate clinical symptoms and normalize the immunological\n      abnormalities.\n\n      The Study Protocol is verify the modifications in the immunological pattern induced by\n      reducing bacteria related activation of immunity by Rifaximin treatment."
        }, 
        "brief_title": "Immunohistology in USDD and Correlation Between Bacterial Flora and Phlogosis", 
        "completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "condition": "Diverticular Disease", 
        "condition_browse": {
            "mesh_term": "Diverticulum"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  male and female\n\n          -  age 18 or more\n\n          -  radiologic or endoscopic diagnosis of diverticular disease located in sigma or colon\n             descendent\n\n          -  Informed consent\n\n          -  patients willing to participate in to the study\n\n        Exclusion Criteria:\n\n          -  other colon diseases\n\n          -  Inflammatory Bowel Diseases\n\n          -  signs or symptoms of inflammation\n\n          -  consumption of : antibiotics, anti-inflammatory drugs ( FANS  and 5-ASA), prebiotics,\n             Proton Pump Inhibitors, corticosteroids, fiber within three months\n\n          -  pregnancy and breast feeding\n\n          -  acute diverticulitis characterized by:\n\n          -  moderate/sever pain in left iliac fossa\n\n          -  fever > 38\u00b0C\n\n          -  abdominal pain\n\n          -  haematochezia\n\n          -  leukocytosis (20% more than the normal range)\n\n          -  remote acute diverticulitis\n\n          -  rifaximin hypersensitivity\n\n          -  neoplastic diseases\n\n          -  immunodeficiencies\n\n          -  poor physical conditions\n\n          -  leaver deficiencies (Child C), kidney (Creatinine>2,2 mg/dl), heart (NYHA 3-4)\n\n          -  major psychiatric illness\n\n          -  drugs abuses and alcoholism\n\n          -  participations in other clinical trials within 4 weeks\n\n          -  patients unwillingness certificate"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "61", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02068482", 
            "org_study_id": "MDSNC2009"
        }, 
        "intervention": {
            "arm_group_label": "1a USDD", 
            "description": "Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months", 
            "intervention_name": "Rifaximin", 
            "intervention_type": "Drug", 
            "other_name": "Normix"
        }, 
        "intervention_browse": {
            "mesh_term": "Rifaximin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Uncomplicated", 
            "Symptomatic"
        ], 
        "lastchanged_date": "February 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rome", 
                    "country": "Italy", 
                    "zip": "00168"
                }, 
                "name": "Cattholic University of the Sacre Heart"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "3", 
        "official_title": "Evaluation of Immunohistological Pattern in Patients With Uncomplicated Symptomatic Diverticular Disease and Correlation Between Intraluminal Bacterial Flora and Phlogosis", 
        "overall_official": [
            {
                "affiliation": "CU Sacred Heart", 
                "last_name": "Franco Pandolfi, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CU Sacred Heart", 
                "last_name": "Lucio Petruzziello, Doctor", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "CU Sacred Heart", 
                "last_name": "Paola Cesaro, Doctor", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "CU Sacred Heart", 
                "last_name": "Rossella Cianci, Doctor", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Lymphocytes in peripheral Blood, Lymphocytes in the Sigmoid Mucosa, Lymphocytes in the Transverse Mucosa, Monocytes and Granulocytes in Peripheral Blood", 
            "measure": "Immunohistological Pattern", 
            "safety_issue": "No", 
            "time_frame": "Two months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02068482"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Catholic University of the Sacred Heart", 
            "investigator_full_name": "Guido Costamagna", 
            "investigator_title": "Director of Digestive and Surgical Endoscopy", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Dyspepsia, Meteorism, Abdominal pain, Tenesmus, Diarrhea, Fever, Fever with Chills, Painful Palpation, VAS, Likert, Numbers of Evacuations", 
            "measure": "Clinical Symptoms", 
            "safety_issue": "No", 
            "time_frame": "Two Months"
        }, 
        "source": "Catholic University of the Sacred Heart", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Catholic University of the Sacred Heart", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}